重酒石酸卡巴拉汀辅助治疗晚期帕金森病患者的效果及其对脑电图的影响  

Effect of rivastigmine bitartrate on electroencephalogram in adjuvant treatment of patients with advanced Parkinson's disease

作　　者：李珂[1] 王献[1] 洪丽[1] Li Ke;Wang Xian;Hong Li(Department of Neurology,Anyang Hospital of Puyang,Anyang 455000,Henan,China)

机构地区：[1]濮阳市安阳地区医院神经内科,河南安阳455000

出　　处：《四川生理科学杂志》2021年第7期1131-1133,1185,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:研究重酒石酸卡巴拉汀在中晚期帕金森病(Parkinson's disease,PD)中的辅助治疗作用。方法:将我科2018年8月至2020年9月期间105例晚期PD患者随机分为两组,对照组患者(n=52)晨起口服司来吉兰(初始计量5 mg,根据患者病情增加至10 mg)治疗,观察组患者(n=53)联合口服重酒石酸卡巴拉汀(初始计量3 mg,根据患者病情酌情增至6 mg)治疗。3 m后,经自主神经症状量表(The scale for outcomes in PD for autonomic symptoms,SCOPA-AUT)、统一帕金森评分量表(Unified Parkinson’s disease rating scale,UPDRS)、PD生活质量问卷(Parkinson’s disease quality life questionnaire-39,PDQL-39)和日常生活能力量表(Activity of daily living,ADL)评价患者临床症状和生活能力;通过JJG954-2000数字脑电图仪/脑电地形图仪评价脑电图表现;Webster症状评分量表评价临床疗效;酶联免疫吸附法测定神经递质水平;并观察不良反应发生情况。结果:与治疗前相比,各治疗组的UPDRS、SCOPA-AUT、PDQL-39评分和不良反应、θ、δ频段相对功率谱平均值均明显降低(P<0.05),其中观察组更为显著(P<0.05);ADL、临床总有效率、hoehn-Yahr分级、5-HT、NE、DA、β1、β2频段相对功率谱平均值均明显升高(P<0.05),其中观察组更为显著(P<0.05)。结论:重酒石酸卡巴拉汀可增强司来吉兰的作用,改善患者脑电图表现以及临床症状,增强患者生活能力。Objective:To study the adjuvant therapeutic effect of rivastigmine bitartrate in advanced Parkinson's disease(PD).Methods:From August 2018 to September 2020,105 patients with advanced PD in our department were randomly divided into two groups.The control group(n=52)received selegiline orally in the morning(initial dose of 5 mg,increased to 10 mg according to the patient’s condition),and the observation group(n=53)received rivastigmine bitartrate orally(initial dose of 3 mg,increased to 6 mg as appropriate).After 3 months treatment,the scale for outcomes in PD for autonomic symptoms(SCOPA-AUT),Unified Parkinson’s disease rating scale(UPDRS),Parkinson’s disease quality life questionnaire-39(PDQL-39)and Activity of daily living(ADL)were used to evaluate the clinical symptoms and living ability;EEG performance was measured by JJG954-2000 digital electroencephalogram/electroencepha-logram topography;Webster symptom score scale was used to evaluate clinical efficacy;enzyme-linked immunoassay was used to measure the levels of neurotransmitter including 5-HT,NE and DA;and the adverse reactions were observed.Results:After treatment,the UPDRS,SCOPA-AUT,PDQL-39 scores,adverse reactions,and the average value of the relative power spectrum of theθandδbands in each treatment group were significantly decreased(P<0.05),and the observation group was more significant(P<0.05);ADL,total clinical effective rate,hoehn-Yahr classification,5-HT,NE,DA,β1,β2 frequency band relative power spectrum average value were significantly increased(P<0.05),among which the observation group was more significant(P<0.05).Conclusion:Rivastigmine bitartrate can enhance the effect of selegiline,improve EEG performance and clinical symptoms of patients,and enhance the life ability of patients.

关 键 词：重酒石酸卡巴拉汀 中晚期帕金森病 脑电图 

分 类 号：R74[医药卫生—神经病学与精神病学]